Emcure Pharma and Sanofi India Announce Exclusive Partnership

In a significant move to enhance diabetes care in India, Emcure Pharma and Sanofi India have entered into an exclusive distribution and promotion agreement. This partnership, effective immediately, will see Emcure exclusively distributing and promoting Sanofi's renowned oral anti-diabetic products, including popular brands like Amaryl and Cetapin.

What This Means for Diabetes Patients in India

This collaboration is set to bring about a transformative change in the accessibility and availability of advanced diabetes treatment options across the country. With Emcure's robust distribution network and Sanofi's innovative product portfolio, patients can look forward to improved care and management of diabetes.

Stay Updated with the Latest in Business and Health

Keep yourself informed with the latest developments in the business and healthcare sectors. From updates on bank holidays to groundbreaking partnerships like this one, we've got you covered.